Gene-based biopharmaceutical company Oxford BioMedica has reported that revenue rose to 7.8m pounds in the full year 2012 from 7.7m pounds one year earlier.
In its preliminary results for the year ending December 31st, the company stated that fundraising of £11.6m was completed in July 2012 with net proceeds £10.1m.
Operational highlights included the Sanofi ocular partnership nearing successful conclusion with $53m committed to date.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company also reported that the ProSavin Phase I/II study successfully met primary endpoints while industry collaborations validated Oxford BioMedica's 5T4 tumour antigen technology.
John Dawson, Chief Executive Officer of Oxford BioMedica, said: "During 2012 we reported positive developments across our core clinical programmes, strengthened our LentiVector technology platform and secured MHRA[UK Medicines and Healthcare products Regulatory Agency] approval for our GMP[good manufacturing practice] manufacturing plant.
"Macroeconomic conditions remain challenging, however sentiment towards the biopharmaceutical sector is improving and we are seeing more interest than ever in personalised medicines and niche disease indications, all of which positions Oxford BioMedica well for further developments in the year ahead."
Oxford BioMedica's share price was up 1.69% to 2.40% to 2.40p at 10:41 on Wednesday.
MF
-
Lloyds, Halifax and Bank of Scotland to shut another 45 branchesLloyds Banking Group, which includes Halifax and Bank of Scotland, is set to close a further 45 branches in 2024 - find out if a branch near you is closing.
-
US stock trading app Robinhood launches in the UK
The low-cost trading platform has opened another waiting list for British investors - following two failed attempts to launch in this country - and is hoping to be fully operational next year.
